How Successful Is Brachytherapy for Prostate Cancer?

Brachytherapy for prostate cancer ranks among the most effective treatments available, with five-year biochemical recurrence-free survival rates in the range of 84–89% for low- and intermediate-risk disease, and strong evidence that it performs comparably to surgery over the long term. The specifics depend on the type of brachytherapy used, the risk category of the cancer, and whether it is combined with other treatments. But the broad picture is reassuring, and the data behind it are now mature enough to cover ten- and even fifteen-year follow-up periods.

What the Long-Term Cure Rates Actually Look Like

When doctors talk about brachytherapy “working,” they usually mean freedom from biochemical recurrence, which is a sustained low PSA level with no sign the cancer has returned. A large study tracking patients treated with low-dose-rate (LDR) brachytherapy found overall biochemical recurrence-free survival of about 84% at five years and roughly 72% at ten years. Those numbers held up across risk groups: low-risk patients had five- and ten-year rates of about 84% and 71%, while intermediate-risk patients came in at about 85% and 76%.¹ A separate single-institution study focusing specifically on low-risk patients treated with iodine-125 seeds confirmed excellent five-year outcomes with few side effects.²

For high-risk prostate cancer, brachytherapy is rarely used alone. Instead, it is combined with external beam radiation and hormone therapy in what is sometimes called tri-modality treatment. A review by the American Brachytherapy Society concluded that the majority of high-risk cancers are curable with this combined approach, with several large studies and three randomized trials showing better biochemical control than dose-escalated external radiation alone.³ A review of the evidence across risk levels found that for low- to intermediate-risk patients, the standout advantage of LDR brachytherapy is its brief treatment time combined with long recurrence-free survival, while for high-risk patients, the tri-modality approach offers excellent disease control.⁴

How Brachytherapy Compares to Surgery

One of the first questions most patients have is whether they would do better with surgery (radical prostatectomy) or radiation. The evidence, accumulated across multiple studies and a meta-analysis, consistently shows no meaningful survival difference between the two for localized disease. A meta-analysis pooling data from multiple studies found biochemical recurrence rates of about 17% for surgery and 16% for brachytherapy, with no statistically significant difference. Prostate cancer-specific mortality was similarly close: around 1.1% for surgery and 0.5% for brachytherapy, again without a statistically significant gap.⁵

A propensity score-matched study comparing the two treatments directly found no statistically significant difference in clinical relapse-free survival, overall survival, or cancer-specific survival.⁶ Even for high-risk disease, one large analysis showed no statistical difference in survival between surgery and external beam radiation combined with brachytherapy, after adjusting for differences in patient characteristics and other medical conditions.⁷

The practical takeaway is that the choice between brachytherapy and surgery usually comes down to side-effect profiles, patient preferences, and anatomy rather than a survival advantage for one over the other. A French study even found that the total societal costs of brachytherapy and surgery were not significantly different at two years after treatment.⁸

The Brachytherapy Boost for Higher-Risk Cancers

Where brachytherapy stands out against other radiation approaches is when it is used as a “boost” on top of external beam radiation. The idea is straightforward: external radiation treats the broader pelvic area, and then brachytherapy delivers a concentrated extra dose directly to the prostate. This combination can safely push the total radiation dose higher than external beam alone could manage.

The ASCENDE-RT trial, one of the most important randomized trials in this space, compared an LDR brachytherapy boost against a dose-escalated external beam boost in men with intermediate- and high-risk prostate cancer, all of whom also received hormone therapy. Men who got external beam alone were twice as likely to experience biochemical failure. The nine-year biochemical progression-free survival was 83% with the brachytherapy boost versus 62% without it. The benefit held for both intermediate- and high-risk patients.⁹

High-dose-rate (HDR) brachytherapy boosts show similar advantages. A randomized trial with 12 years of follow-up found that adding an HDR brachytherapy boost to external radiation produced a 21% improvement in relapse-free survival and roughly doubled the median time to relapse compared to external radiation alone.¹⁰ HDR brachytherapy has an inherent technical advantage here: because the radiation source is temporarily placed and then removed, clinicians can fine-tune the dose distribution by adjusting how long the source dwells in each position. This flexibility allows dose escalation that would be difficult with permanent seed implants.¹¹

For intermediate-risk disease specifically, a comparison between brachytherapy alone and external beam radiation alone showed a striking gap over ten years. Freedom from biochemical failure was about 82% with brachytherapy versus roughly 55% with external radiation.¹² The concentrated dose that brachytherapy delivers directly to the prostate appears to provide a meaningful edge over conventional external radiation for cancers that fall in the middle of the risk spectrum.

Urinary Side Effects and Recovery

Urinary symptoms are the most common side effect of prostate brachytherapy, and virtually everyone should expect some degree of trouble in the first few months. Studies have consistently reported that up to 84% of patients experience urinary symptoms in the acute phase, mostly mild irritation and obstruction: needing to urinate frequently, urgency, a weak stream, and discomfort during urination. These are caused by a combination of physical trauma from needle insertion and the radiation-induced inflammatory response that follows.¹³

The good news is that these acute symptoms typically resolve. In the MD Anderson experience, all urinary symptom scores had returned to baseline levels by eight months after implantation. Late complications, meaning those appearing after the acute phase, were less common and graded by severity: about 9% were grade 1 (minor), 7% were grade 2 (moderate, including urethral stricture and intermittent blood in the urine), roughly 2% were grade 3 (requiring catheterization or causing severe symptoms), and 0.5% were grade 4 (in this case, severe hemorrhagic cystitis).¹⁴ Serious long-term urinary problems are uncommon, but they do happen, and anyone considering the procedure should know the range of possibilities.

Sexual Function After Brachytherapy

Erectile function after prostate brachytherapy is a real concern and the data here are more variable than the cancer control numbers. How well erections are preserved depends heavily on a man’s age, his baseline sexual function before treatment, whether brachytherapy was combined with external radiation, and whether he has conditions like diabetes.

One study with six years of follow-up reported that 39% of men maintained potency after brachytherapy without any medication. The strongest predictors were how good erectile function was before the procedure, patient age, and whether supplemental external radiation was used. Younger men (under 60) preserved potency at about 57%, compared to roughly 38% for men in their 60s and about 22% for men 70 and older. Diabetes eliminated potency preservation entirely in that cohort. Importantly, when men who responded to erectile dysfunction medication were counted, the six-year potency rate jumped to 54%, and when potent men plus those who successfully used sildenafil were combined, the rate reached 92%.¹⁵

A separate study found a three-year potency preservation rate of about 51%, broadly consistent with the longer-term data.¹⁶ Another study explored whether taking a low daily dose of tadalafil (a drug in the same family as Viagra) around the time of the procedure could help. At two years, 76% of men who had been potent before treatment remained so, and 89% had erections firm enough for sexual activity.¹⁷ These results suggest that proactive use of erectile-function medications may meaningfully improve outcomes, though patient selection in these studies tends to favor men who were functioning well to begin with.

Reducing Rectal Side Effects

Bowel and rectal symptoms are less common than urinary complaints but remain a legitimate concern, particularly rectal bleeding. One advance that has made a measurable difference is the use of hydrogel spacers, a gel injected between the prostate and the rectum before treatment to physically push the rectum away from the radiation field.

A systematic review found that hydrogel spacers significantly reduced the radiation dose reaching the rectum during brachytherapy, and retrospective data suggested this translated into less rectal toxicity.¹⁸ A study looking specifically at patient-reported rectal bleeding after brachytherapy with cesium-131 seeds found that men who received the spacer had dramatically less long-term bleeding: a cumulative incidence of about 3% versus 19% in those without the spacer.¹⁹ That is a substantial difference, and hydrogel spacers are increasingly considered standard practice at centers that perform brachytherapy regularly.

The Question of Secondary Cancers

Any radiation treatment carries a small long-term risk of causing a new cancer in nearby tissue, and brachytherapy is no exception. The risk is generally lower than with external beam radiation because the radiation is delivered so close to the tumor that surrounding organs receive a smaller dose. A review of risk factors for secondary bladder cancer after prostate radiation found that brachytherapy was associated with smaller increased risks compared to external beam radiation, owing to its more targeted delivery.²⁰

That said, the risk is not zero. A large population-based analysis with propensity score matching found that the 20-year incidence of a secondary bladder cancer was about 6% after brachytherapy compared to roughly 2.4% after surgery, and the 20-year incidence of secondary rectal cancer was about 1.1% after brachytherapy versus 0.5% after surgery.²¹ A Japanese cohort with a median follow-up of almost nine years found secondary tumors in about 2.7% of patients, split between bladder and rectal/anal canal cancers, and noted that higher radiation doses to the prostate were associated with increased risk.²²

These numbers deserve some context. Prostate cancer is typically diagnosed in men in their 60s and 70s, and the secondary cancer risk plays out over decades. For many men, competing health risks will be more relevant than this small incremental cancer risk. But it is a factor worth knowing about, particularly for younger patients with decades of life expectancy ahead of them.

What If the Cancer Comes Back?

A diagnosis of biochemical recurrence after brachytherapy does not necessarily mean the situation is dire, but the salvage options are more limited than after surgery. Re-treating with brachytherapy (sometimes called “reseeding”) is one option. In one study of 21 men who underwent salvage brachytherapy after initial brachytherapy, about 52% remained free of biochemical recurrence at a mean follow-up of roughly five years. For those who did fail again, the median time to second failure was about 25 months.²³ A smaller series using partial salvage brachytherapy targeting just the area of recurrence found that most patients tolerated the retreatment well, with PSA levels dropping and no significant toxicity, though two of seven patients progressed within about a year.²⁴

These are small studies and the evidence base for salvage brachytherapy is still thin. Other salvage options after a failed first round of brachytherapy include surgery (salvage prostatectomy), cryotherapy, and high-intensity focused ultrasound, each with its own trade-offs in terms of cancer control and side effects. The main point is that recurrence after brachytherapy is not a dead end, but the retreatment landscape is more complicated and less well studied than primary treatment.

How Imaging Technology Is Changing Brachytherapy

Modern brachytherapy bears little resemblance to its early history. The procedure dates back over a century, but results were inconsistent until transrectal ultrasound was developed in the 1980s, allowing doctors to see where they were placing the radioactive seeds in real time. Subsequent advances in computer planning software turned it into a single-session procedure with precise dose calculations done during the operation itself.²⁵

The current frontier is the fusion of MRI data with real-time ultrasound. MRI is much better than ultrasound at identifying exactly where a tumor sits within the prostate, and when those images are registered to the ultrasound used during the procedure, it becomes possible to target the tumor itself rather than treating the entire gland. A systematic review found that combining MRI with ultrasound provides efficient tumor mapping during the procedure, and existing treatment-planning software already supports this workflow.²⁶

This is enabling focal brachytherapy, where only the part of the prostate containing cancer receives the full therapeutic dose, sparing the rest of the gland. A feasibility study of MRI-targeted single-fraction HDR brachytherapy showed that catheters could be placed accurately and the maximum dose restricted to the tumor, with the procedure proving safe for individual patients.²⁷ Focal treatment could, in theory, preserve more urinary and sexual function while still controlling the cancer, though it remains early-stage and is not yet standard of care. For men with a well-defined, visible tumor on MRI, it represents a genuinely promising direction.

Why Operator Experience Matters

Brachytherapy is a hands-on procedure, and outcomes depend in part on how well the radioactive sources are placed. The quality of the implant directly affects the radiation dose distribution within the prostate, which in turn affects both cancer control and side effects. Treatment outcomes vary with the skill of the operator and the rigor of patient selection.²⁸ Interestingly, at least one study looking at provider case volume found that complication rates after brachytherapy were not linked to how many procedures a physician performed, suggesting that formal training and technique matter more than raw volume.²⁹

Still, patients should ask about their institution’s brachytherapy program, including whether it uses real-time dosimetric planning, what imaging technology is available, and how many procedures the team performs annually. The underlying physics of seed placement and dose delivery are demanding, and the difference between a good implant and a suboptimal one can show up years later in both cancer control and quality of life. LDR brachytherapy using iodine-125, cesium-131, or palladium-103 seeds each deliver radiation at different rates and over different timeframes, and the treatment plan must account for these differences carefully.³⁰ Centers with established brachytherapy programs, modern planning systems, and multidisciplinary teams tend to produce the most consistent results.